Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 186.00
+2.00 (1.09%)
At close: Jan 30, 2026
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
€635,740
Profits / Employee
€229,047
Market Cap
11.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Jan 1, 2023 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Paul Hartmann AG | 10,082 |
| Mainova AG | 3,416 |
| Gelsenwasser AG | 1,898 |
| Maschinenfabrik Berthold Hermle AG | 1,607 |
| EUROKAI GmbH & Co. KGaA | 950 |
| tonies SE | 567 |
| Lechwerke AG | 459 |
| Northern Data AG | 199 |
Ascendis Pharma News
- 17 days ago - Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? - Nasdaq
- 19 days ago - Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript - GuruFocus
- 19 days ago - Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Ascendis Pharma (ASND) Focuses on Core Plans Amidst Market Conditions - GuruFocus
- 22 days ago - Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 22 days ago - Ascendis Pharma (ASND) Receives Increased Price Target from Wells Fargo | ASND Stock News - GuruFocus
- 22 days ago - Ascendis Confirms Durable Growth Benefits In Achondroplasia In COACH Trial - Nasdaq
- 23 days ago - Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript - Seeking Alpha